SLC5A2 and Cognitive impairment: In addition, increasing evidence suggests that the use of sodium-glucose cotransporters-2 inhibitors, another class of novel anti-diabetic therapeutic agents, may be associated with improved cognitive deficits, although the exact mechanisms involved are still not fully elucicated (14).